Introducing new capabilities to GPT-Rosalind

We’re introducing a new model update to our GPT‑Rosalind series purpose-built for life sciences research at enterprise scale. It combines GPT‑5.5’s agentic coding and tool-use capabilities with stronger model intelligence in core drug-discovery domains such as medicinal chemistry and genomics, while advancing performance across broader life sciences analysis, design, and experimental workflows.

Progress in life sciences depends on synthesizing data and evidence across scales and modalities: molecules, genes, pathways, and living systems. In our evaluations, the updated GPT‑Rosalind shows broad performance gains on research tasks from biology experts, complex medicinal chemistry queries, quantitative biology, and wet lab troubleshooting.

GPT‑Rosalind is now available in research preview to eligible organizations globally through our trusted-access deployment structure.

In order to measure and continuously improve the real-world impact of GPT‑Rosalind, we designed LifeSciBench, an externally expert-judged benchmark focused on foundational aspects in life sciences research. Unlike existing benchmarks that evaluate a single component of model performance or biological domain in isolation, LifeSciBench takes an end-to-end view of scientifically valuable work by drawing tasks from six workflow areas central to life sciences research: evidence handling, analysis, design and optimization, scientific reasoning, validation and operations, and translation and communication. We use this benchmark to align progress with the needs and realities of life sciences research.

Extracting, reconciling, and auditing scientific evidence from papers, figures, tables, and experimental records.

Eval Example

We’re preparing for a Type B FDA meeting on AAV9-microDys-X, an AAV9-based micro-dystrophin gene therapy for Duchenne muscular dystrophy that expresses a 138 kDa construct from an MCK promoter, and we want a hard-nosed critique of whether our current package really supports accelerated approval on micro-dystrophin expression as a surrogate endpoint reasonably likely to predict clinical benefit.

Study context: open-label Phase 1b/2 in 12 ambulatory boys age 4–7 with confirmed DMD and out-of-frame rod-domain deletions. The package is:

• Pre-treatment vastus lateralis biopsies: 0–3% of healthy-control dystrophin by quantitative Western blot using MANEX1A against the N-terminal actin-binding domain.
• 12-week post-treatment contralateral vastus lateralis biopsies: mean micro-dystrophin 38% of healthy control (range 18–61%) by the same Western blot, normalized to total protein by Coomassie staining.
• Post-treatment immunofluorescence: sarcolemmal signal in 75–95% of fibers using a polyclonal anti-dystrophin C-terminal antibody.
• 48-week function: mean NSAA change +1.4 points from baseline versus −0.6 in an external published natural-history registry cohort (p = 0.03 by unpaired t-test).
• Safety: transient transaminitis in 8/12 patients managed with steroid taper; one resolved myocarditis; no deaths.
• Biodistribution/persistence: AAV9 vector genomes detectable in muscle at 12 weeks at a mean of 2.3 vector genomes per nucleus.
• Eligibility: no baseline anti-AAV9 neutralizing antibodies (titer <1:400) and no exon-44 deletions.

Please pressure-test this package item by item: where would FDA or a skeptical reviewer say the evidence, as presented, fails to support our conclusion, and what additional data, analyses, or design changes would be needed to close those gaps if possible? For anything not specified, assume what is known from other clinical-grade 138 kDa micro-dystrophin programs and relevant clinical trials through December 31, 2025 also applies.

Candidate Response

Bottom line: As presented, this package is not strong enough to support accelerated approval on micro-dystrophin expression as a surrogate endpoint reasonably likely to predict clinical benefit. A skeptical FDA reviewer would likely view the biomarker, functional, durability, safety, and generalizability evidence as materially under-supported.

Package Item | Key Failure Mode | What Would Be Needed | |---|---|---| Western blot quantification | MANEX1A binds an N-terminal epitope shared by endogenous full-length dystrophin and the micro-dystrophin transgene, so the assay does not cleanly distinguish transgene from residual/revertant dystrophin. Quantifying a 138 kDa micro-dystrophin against a healthy full-length dystrophin standard is also invalid. | Use a recombinant micro-dystrophin standard and an orthogonal method that distinguishes transgene from endogenous dystrophin, such as targeted mass spectrometry or a transgene-specific/epitope-specific assay. | Immunofluorescence | The C-terminal polyclonal antibody is poorly suited because the 138 kDa construct lacks the C-terminal domain. Many DMD patients have revertant fibers, and revertant dystrophin can retain C-terminal epitopes. Revertant fibers may expand clonally with age, biasing IF signal, especially in older boys. | Repeat IF with an antibody against an epitope present in the transgene but absent from revertant dystrophin. Quantify transgene-positive fibers separately from revertant fibers. | Surrogate endpoint validity | The package conflates protein amount with clinical function. “38% of healthy-control protein mass” does not mean 38% of normal dystrophin function because micro-dystrophin is structurally truncated. | Empirically validate the relationship between micro-dystrophin mass-percent, sarcolemmal localization, downstream functional restoration, and clinical benefit before treating expression as a surrogate endpoint. | Biopsy design | Pre- and post-treatment contralateral vastus lateralis biopsies introduce left-right and intramuscular spatial variability. Disease progression and fibro-fatty replacement can also change total-protein-normalized signal. | Standardize biopsy site using consistent anatomical landmarks, normalize to muscle-specific proteins, and measure fibro-fatty composition in parallel. | NSAA comparator/statistics | An external natural-history cohort is not a randomized concurrent control. Trial eligibility, supportive care, participation effects, baseline NSAA, steroid regimen, age, and exon class can all bias the comparison. An unpaired t-test is not sufficient. Also, a +1.4 NSAA change is within test-retest variability for this age group. | Run a randomized concurrent placebo-controlled study, or at minimum use adjusted analyses accounting for baseline NSAA, age, steroid regimen, exon class, and other confounders. | Age-window confounding | Boys age 4–7 are in a developmental window where untreated ambulatory DMD patients may gain motor function before decline dominates. A 48-week NSAA change mixes developmental gain, disease progression, and possible treatment effect. | Use a concurrent randomized control with age stratification to separate developmental trajectory from treatment effect. | Prior clinical precedent | Open-label micro-dystrophin functional signals have not reliably predicted confirmatory benefit; published precedent includes micro-dystrophin gene therapy confirmatory trials failing to reproduce open-label NSAA improvements. | Do not rely on open-label NSAA change as decisive support. Require controlled functional evidence. | Structural limits of the construct | The 138 kDa construct deletes spectrin repeats R16/17, which contain nNOS-binding sites. Loss of nNOS recruitment can impair functional sympatholysis and ischemia protection during exercise, creating a mechanistic ceiling on rescue independent of expression level. | Add mechanistic studies showing whether this specific construct restores relevant dystrophin-associated complex function, nNOS localization, exercise physiology, and muscle protection. | AAV durability | Vector genomes at 12 weeks do not establish durable expression. AAV9 genomes are largely non-integrating episomes and may decline over time. Vector-genome persistence